Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

5274 ARTÍCULOS , VIENDO DEL 796 AL 810

c-Abl Inhibitors as Disease-Modifying Therapies for Parkinson's Disease: Gaps and Opportunities

Merchant K, Sullivan J.

Mov Disord. 2022 Jan;37(1):3-5. doi: 10.1002/mds.28907.

Bacopa monnieri for Disorders Affecting Brain: Current Perspectives

Vinod A, Sathianarayanan S, Babu AE, Sadanandan P, Venu AK, Venkidasamy B.

Curr Top Med Chem. 2022;22(23):1909-1929. doi: 10.2174/1568026622666220119111538.

Air Pollution and the Risk of Parkinson's Disease: A Review

Murata H, Barnhill LM, Bronstein JM.

Mov Disord. 2022 May;37(5):894-904. doi: 10.1002/mds.28922. Epub 2022 Jan 19.

[Relevance of COMT inhibitors in the treatment of motor fluctuations]

Jost WH, Buhmann C, Classen J, Eggert K, Kohl Z, Outeiro T, Tönges L, Woitalla D, Reichmann H.

Nervenarzt. 2022 Oct;93(10):1035-1045. doi: 10.1007/s00115-021-01237-3. Epub 2022 Jan 19.

Pre-excitation Due to Fascicular-Ventricular Pathway: An Electrocardiographic Diagnosis: A Case Report

Lange RA, Nguyen V, Abedin Z.

J Investig Med High Impact Case Rep. 2022 Jan-Dec;10:23247096211073261. doi: 10.1177/23247096211073261.

Parkinsonism and prolonged cognitive decline as a manifestation of cryptococcal meningitis in a renal transplant patient

Nelles R, Britton S, John GT, Denaro C.

BMJ Case Rep. 2022 Jan 19;15(1):e245788. doi: 10.1136/bcr-2021-245788.

Altered blood-brain barrier and blood-spinal cord barrier dynamics in amyotrophic lateral sclerosis: Impact on medication efficacy and safety

Pan Y, Nicolazzo JA.

Br J Pharmacol. 2022 Jun;179(11):2577-2588. doi: 10.1111/bph.15802. Epub 2022 Feb 7.

A Randomized Trial Assessing the Safety, Pharmacokinetics, and Efficacy During Morning Off of AZ-009

Thijssen E, den Heijer J, Puibert D, Moss L, Lei M, Hasegawa D, Keum K, Mochel K, Ezzeldin Sharaf M, Alfredson T, Zeng W, van Brummelen E, Naranda T, Groeneveld GJ.

Mov Disord. 2022 Apr;37(4):790-798. doi: 10.1002/mds.28926. Epub 2022 Jan 20.

Scrambler Therapy for the Treatment of Multiple System Atrophy-Parkinsonian Subtype Pain: A Case Report

Wang EJ, Berninger LE, Pantelyat AY, Hunsberger JB, Smith TJ.

A A Pract. 2022 Jan 18;16(1):e01560. doi: 10.1213/XAA.0000000000001560.

New approaches to treatments for sleep, pain and autonomic failure in Parkinson's disease - Pharmacological therapies

Rukavina K, Batzu L, Leta V, Chaudhuri KR.

Neuropharmacology. 2022 May 1;208:108959. doi: 10.1016/j.neuropharm.2022.108959. Epub 2022 Jan 17.

Carving the senescent phenotype by the chemical reactivity of catecholamines: An integrative review

Golubev AG.

Ageing Res Rev. 2022 Mar;75:101570. doi: 10.1016/j.arr.2022.101570. Epub 2022 Jan 18.

Clinical Review of Smartphone Applications in Parkinson's Disease

Tripathi S, Malhotra A, Qazi M, Chou J, Wang F, Barkan S, Hellmers N, Henchcliffe C, Sarva H.

Neurologist. 2022 Jul 1;27(4):183-193. doi: 10.1097/NRL.0000000000000413.

Neuroprotection and Disease Modification by Astrocytes and Microglia in Parkinson Disease

Takahashi S, Mashima K.

Antioxidants (Basel). 2022 Jan 17;11(1):170. doi: 10.3390/antiox11010170.

Piperine and Its Metabolite's Pharmacology in Neurodegenerative and Neurological Diseases

Azam S, Park JY, Kim IS, Choi DK.

Biomedicines. 2022 Jan 12;10(1):154. doi: 10.3390/biomedicines10010154.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias